EHC insider plans sale of 1,020 RSU shares via UBS on NYSE
Rhea-AI Filing Summary
Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider RSU sales planned; size (~$126k) is small relative to a large-cap issuer and likely immaterial to operations.
The filing documents a notice-of-intent to sell 1,020 shares acquired via RSU vesting in early 2023, executed through UBS on the NYSE. Because the aggregate value is modest, this appears to be a routine liquidity event rather than a signal of company-specific deterioration. The filer affirms no undisclosed material adverse information and reports no other sales in the prior three months.
TL;DR: Compliance disclosure consistent with Rule 144; timing and certification follow standard insider-sale protocols.
The Form 144 provides required details: acquisition method (RSU vesting), acquisition dates, planned sale date, broker, and market value. The signed representation that no material nonpublic information exists aligns with governance expectations when insiders sell. There is no indication of clustered or repeated large insider disposals in this filing.